Jelly Force disclaimer

Dietary supplements in the United States are not approved by the Food and Drug Administration before they go on sale. There is no approval for this product to hold, and any page anywhere claiming one for a supplement is wrong on a point of fact rather than of opinion.

What a supplement may say about itself is a structure and function statement: that it supports something the body already does. What it may not say is that it treats, prevents or cures a condition. The four supports on the seller's page and the three words on the bottle are structure and function statements, and they are the ceiling on this whole website.

The Federal Trade Commission's health-claims guidance sets out the standard of evidence a marketer is expected to hold behind a claim like that, and it is stricter than most shelves behave. The NCCIH guidance on using supplements wisely is the corresponding advice for a reader.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Individual results vary. That sentence appears on every page in this category and it is worth unpacking rather than repeating.

The review figures on this site — 4.8 out of 5, 1,165 written reviews, 8,260 orders, 91% recommending — belong to the distributor. They are its summary of its own sales, not audited transcripts, and they are not evidence about the formula. A seller's review panel is a filtered sample by construction.

The eight reviewer entries published here have no control group and report subjective outcomes. Every randomised trial cited on this site needed a placebo arm to say anything, and in the ashwagandha trial in men of 40 to 70 the placebo arm erased the difference in how the men reported feeling.

What acts on the things this bottle is sold for, with randomised evidence behind it, includes sleep, weight, alcohol, blood pressure and movement. None of those is sold here, and a page that lists them is more use to a reader than one that does not.

Every citation here was pulled from the NCBI E-utilities in the build session and the reference line written from the fields returned: authors, journal, year, volume, issue, pages. The amount each trial used was read out of its abstract, which is why those amounts appear beside the ingredient names rather than in a vague sentence.

All 28 PubMed records were re-read at paper level for a retraction, expression of concern or erratum notice, and none carries one. The author-level pass returned large counts for several common surname-plus-initial strings; those are different people in different fields and are a property of PubMed's author index rather than a finding about these papers. One author of the tribulus trial is a middle author on an unrelated retracted oncology paper; the trial itself carries no notice, and it is cited with its manufacturer co-author named.

None of the studies cited here is a study of this product. No trial of these nine ingredients together, at these amounts, in this format, exists. A citation on this site supports a statement about an ingredient, and nothing on this site claims the gummy inherits a trial's result.

Because a reader deciding how much weight to give a page is entitled to know who is paid when they click the button.

Jellyfoarce is a retail counter. It makes money when somebody buys through it, and every order button on this site hands you to the seller's own checkout, where the payment is taken. That is the whole commercial arrangement and there is nothing hidden behind it: no separate affiliate network is disclosed on any page here because there is none, and no payment has been taken from anybody in exchange for a favourable sentence.

The conflict that creates is real and it does not go away by being mentioned. What can be done about it is to publish the things that count against the product in the same typeface as the things that count for it, and to link the sources so a reader can check rather than trust. On this site that means the dosage comparison, the ashwagandha liver literature and the category analysis that puts 80% of these products in a no-expected-efficacy cluster all appear on the commercial pages rather than in a corner.

It also means the one thing a retail desk is most tempted to do is not done here: no crossed-out comparison price appears anywhere on this site, because the seller prints none. A discount that was never a discount is the cheapest lie in retail and the hardest for a reader to catch.

The bottle prints a full Supplement Facts panel: an 82 mg proprietary blend, equivalent to approximately 567 mg of dry powders, holding nine named ingredients, with caffeine at 5 mg the only one given its own amount. That is a real, checkable ceiling and it is more than many botanical gummies publish anywhere.

What the panel keeps back is the split between the other eight names, which a proprietary blend is allowed to do. The list’s descending order of weight bounds them, and no figure beyond those bounds is estimated anywhere on this website, in any table, on any page.

The seller’s advertising names five of the nine ingredients. The panel is the regulated statement on the container, so it is the list this website follows.

Lot JEL-26/JE-6975 and certificate reference JEL-6975-26-JE identify a production run and a filing. Neither is a laboratory result, no laboratory report for this lot has been supplied to this desk, and none is presented here as though it had.

The money-back window is a promise about money. 60 days from the date of purchase says what the seller will do about a payment. It says nothing about what the gummy will do, and it should not be read as though it did.